ES2587932T3 - Composiciones para su uso en el alivio de los síntomas asociados con el síndrome premenstrual y el trastorno disfórico premenstrual - Google Patents
Composiciones para su uso en el alivio de los síntomas asociados con el síndrome premenstrual y el trastorno disfórico premenstrual Download PDFInfo
- Publication number
- ES2587932T3 ES2587932T3 ES14155548.2T ES14155548T ES2587932T3 ES 2587932 T3 ES2587932 T3 ES 2587932T3 ES 14155548 T ES14155548 T ES 14155548T ES 2587932 T3 ES2587932 T3 ES 2587932T3
- Authority
- ES
- Spain
- Prior art keywords
- nutritional
- pharmaceutical composition
- pms
- pmdd
- symptoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 67
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 title claims abstract description 49
- 208000024891 symptom Diseases 0.000 title claims abstract description 47
- 206010036618 Premenstrual syndrome Diseases 0.000 title abstract 3
- 239000011777 magnesium Substances 0.000 claims abstract description 26
- 235000016709 nutrition Nutrition 0.000 claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 18
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims abstract description 10
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 10
- 239000004615 ingredient Substances 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 229940091250 magnesium supplement Drugs 0.000 claims description 9
- 239000004337 magnesium citrate Substances 0.000 claims description 6
- 229960005336 magnesium citrate Drugs 0.000 claims description 6
- 235000002538 magnesium citrate Nutrition 0.000 claims description 6
- 159000000003 magnesium salts Chemical class 0.000 claims description 6
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 239000000395 magnesium oxide Substances 0.000 claims description 4
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 3
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 2
- 239000000347 magnesium hydroxide Substances 0.000 claims description 2
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 2
- 235000012254 magnesium hydroxide Nutrition 0.000 claims description 2
- 235000012245 magnesium oxide Nutrition 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
- 238000009472 formulation Methods 0.000 description 46
- 238000011282 treatment Methods 0.000 description 45
- 230000005906 menstruation Effects 0.000 description 18
- 208000013404 behavioral symptom Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 230000001186 cumulative effect Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 238000011269 treatment regimen Methods 0.000 description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 229960001153 serine Drugs 0.000 description 4
- 238000013383 initial experiment Methods 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 230000002747 voluntary effect Effects 0.000 description 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010006262 Breast inflammation Diseases 0.000 description 1
- 206010006298 Breast pain Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 206010056465 Food craving Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000006662 Mastodynia Diseases 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 125000005313 fatty acid group Chemical group 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 206010020765 hypersomnia Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- -1 lysophospholipids Chemical class 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000005186 women's health Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
- A23V2250/161—Magnesium
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Polymers & Plastics (AREA)
- Reproductive Health (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/773,653 US9119865B2 (en) | 2009-10-27 | 2013-02-22 | Compositions and methods for alleviating symptoms associated with premenstrual syndrome and premenstrual dysphoric disorder |
| US201313773653 | 2013-02-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2587932T3 true ES2587932T3 (es) | 2016-10-27 |
Family
ID=50112837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14155548.2T Active ES2587932T3 (es) | 2013-02-22 | 2014-02-18 | Composiciones para su uso en el alivio de los síntomas asociados con el síndrome premenstrual y el trastorno disfórico premenstrual |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP2769725B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP5963791B2 (cg-RX-API-DMAC10.html) |
| DK (1) | DK2769725T3 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2587932T3 (cg-RX-API-DMAC10.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106307542A (zh) * | 2016-08-18 | 2017-01-11 | 无锡市利贝乐贸易有限公司 | 具有清调补功能的婴幼儿植物营养补充剂及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL139224A (en) * | 2000-10-23 | 2009-09-01 | David Rutenberg | Anti depressant, stress suppressor and mood improver |
| IL158139A0 (en) * | 2003-09-25 | 2004-09-27 | Enzymotec Ltd | Stabilized formulations of phosphatidyl serine |
| EP1661575A1 (en) * | 2004-11-26 | 2006-05-31 | ZAMBON GROUP S.p.A. | Use of magnesium in the treatment of disorders related to hormonal variations in women |
| US8399432B2 (en) | 2009-10-27 | 2013-03-19 | Lipogen Ltd. | Compositions and methods of treatment for alleviating premenstrual syndrome symptoms |
-
2014
- 2014-02-18 DK DK14155548.2T patent/DK2769725T3/en active
- 2014-02-18 EP EP14155548.2A patent/EP2769725B1/en active Active
- 2014-02-18 ES ES14155548.2T patent/ES2587932T3/es active Active
- 2014-02-19 JP JP2014029125A patent/JP5963791B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2769725A1 (en) | 2014-08-27 |
| JP2014162795A (ja) | 2014-09-08 |
| DK2769725T3 (en) | 2016-08-22 |
| EP2769725B1 (en) | 2016-06-29 |
| JP5963791B2 (ja) | 2016-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100680121B1 (ko) | (리소-)포스파티딜세린을 포함하는 온혈동물에서 스트레스상태의 예방 및 치료용 제제 | |
| KR101975729B1 (ko) | 발기 부전 치료를 위한 조성물 및 방법 | |
| WO2016149424A1 (en) | Phytocomplexes exhibiting multiple, synergistic antioxidant activities useful in foods, dietary supplements, cosmetics and pharmaceutical preparations | |
| US20190209491A1 (en) | Compositions of ketogenic sources, micronutrients and phytochemicals for prophylaxis and mitigation of migraine headache | |
| US20150157672A1 (en) | Kits and methods for sustained weight loss | |
| CN105451749B (zh) | 吸附雄蜂幼虫匀浆和维生素d3或d族维生素和/或其活性代谢物在病毒性疾病的预防和治疗中的应用 | |
| CN102058694B (zh) | 一种氨基酸和提取物组成的药用组合物的用途 | |
| UA91028C2 (ru) | Использование лавандового масла для профилактики и лечения соматических расстройств и посттравматического стресса | |
| US20190000125A1 (en) | Compositions and methods for treating aging and/or improving human health | |
| RU2517217C1 (ru) | Средство для профилактики синдрома хронической усталости у мужчин | |
| JP5963791B2 (ja) | 月経前症候群に付随する症状及び月経前不快気分障害を緩和するのに使用される組成物 | |
| ES2859524T3 (es) | Composición para el uso en el tratamiento de la disforia, la depresión y/o los cambios de ánimo relacionados con el síndrome premenstrual (SPM) | |
| JP2022519320A (ja) | 便秘および胃腸系の他の疾患の治療のための組成物および方法 | |
| US9119865B2 (en) | Compositions and methods for alleviating symptoms associated with premenstrual syndrome and premenstrual dysphoric disorder | |
| US12029771B2 (en) | Neem for treatment of RLS | |
| IT201800003814A1 (it) | Formulazione a base di caffe' in polvere | |
| JP2009263384A (ja) | Ｉ型アレルギー性疾患のアトピー性皮膚炎の症状を抑制するための内服薬 | |
| ES2569302A1 (es) | Composición terapéutica de aceites esenciales para el alivio sintomático de los sofocos de la menopausia y su uso | |
| CN103239571B (zh) | 一种用于治疗斑秃的中药有效部位组合物及其制备方法 | |
| JP2009263385A (ja) | Ｉ型アレルギー性疾患の鼻炎の症状を抑制するための内服薬 | |
| Downey | A New Way To Manage Depression Without Drugs | |
| ZA200400830B (en) | Formulation containing (lyso-) phosphatidylserine for the prevention and treatment of stress states in warm-blooded animals. | |
| US20110245212A1 (en) | Methods of alleviating the symptoms of premenstrual syndrome/late luteal phase dysphoric disorder | |
| JP2009263386A (ja) | Ｉ型アレルギー性疾患の花粉症の症状を抑制するための内服薬 | |
| JP2009256364A (ja) | 動物のオスおよびメス、およびヒトにおける受精能の健康状態を改善するための方法および組成物 |